Ghrelin - TheraSource

Drug Profile

Ghrelin - TheraSource

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TheraSource
  • Developer The Feinstein Institute for Medical Research; TheraSource
  • Class Peptide hormones
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Acute radiation syndrome; Stroke

Highest Development Phases

  • Preclinical Acute radiation syndrome; Stroke

Most Recent Events

  • 03 Aug 2016 Preclinical development in Stroke is ongoing in USA
  • 03 Aug 2016 Ghrelin - TheraSource is available for licensing as of 04 Aug 2016.
  • 12 May 2016 TheraSource receives a phase II SBIR grant from the National Institute of Allergy and Infectious Diseases for ghrelin development in Acute radiation syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top